This article serves as a review of the current literature regarding the role of edoxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and the treatment of venous thromboembolism (VTE).
Summary
Until recent years, oral treatment options for both treatment and prevention of VTE and stroke were limited to warfarin. Dabigatran was the first new oral anticoagulant approved in over 50 years followed by rivaroxaban and apixaban. These new oral anticoagulants offer many benefits over warfarin. Edoxaban is the newest member among the oral anticoagulants and exerts its action by direct inhibition of factor Xa. It may offer some advantages in that it is the second Food and Drug Administration-approved once-daily anticoagulant available and does not interact with the cytochrome P450 (CYP450) system. However, there are concerns in patients with AF and preserved renal function (>95 mL/min), as these cohorts experienced a higher incidence of stroke in trials.
Conclusion
Based on the 3 clinical trials, edoxaban appears to be a safe and effective factor Xa inhibitor in patients with a creatinine clearance of <95 mL/min. It will serve as an alternative anticoagulant for those with a preference for once-daily dosing and/or taking medications that interact with the CYP450 system.
JanuaryCTWannLSAlpertJS. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;64(21):e1–e76.
2.
American College of Chest Physicians Evidence Based Guidelines. Prevention of VTE in Orthopedic Surgery Patients. Chest. 2012;141(2suppl):e278S–e325S.
3.
American College of Chest Physicians Evidence Based Guidelines. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis. Chest. 2012;142(6):1698–1704.
4.
ColillaSUCrowANPedkunWI. Estimates of current and future incidence of atrial fibrillation in the U.S. adult population. Am J Cariol. 2013;112(8):1142–1147.
5.
KannelWBWolfPABenjaminEJ. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9N.
6.
WolfPAAbbottRDKannelWB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561–1564.
7.
MillerPSAnderssonFLKalraL. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?Stroke. 2005;36(2):360–366.
RuffCTGiuglianoRPBraunwaldE. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
12.
OgataKMendell-HararyJTachibanaM. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010:50(7):743–753.
MendellJNoveckRShiM. A randomized trial of safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2012;75(4):966–978.
20.
MendellJZahirHMatsushimaN. Drug–drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331–342.
21.
YamashitaTAKoretsuneYUYasakaMA. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76(8):1840–1847.
22.
ChungNJeonHKLienLM. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost. 2011;105(3):535–544.
23.
WeitzJIConnollySJPatelI. Randomized, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–641.
24.
SuzukiSYamashitaTKatoT. Incidence of major bleeding complications of warfarin therapy in Japanese patients with atrial fibrillation. Circ J. 2007;71(5):761–765.
25.
RaskobGCohenATErikssonBI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose–response study. Thromb Haemost. 2010;104(3):642–649.
26.
FujiTFujitaSTachibanaSKawaiY. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8(11):2458–2468.
27.
GiuglianoRPRuffCTBraunwaldE. Edoxaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
28.
Hokusai-VTE Investigators, BüllerHRDécoususH. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
29.
FujiTFujitaSKawaiY. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res. 2014;133(6):1016–1022.
30.
KurodaYAHirayamaCHHotodaHI. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag. 2013;9:593–598.
